Back to search

Article

24-Nor-ursodeoxycholic acid counteracts T <sub>H</sub> 17/Treg imbalance and ameliorates intestinal inflammation by restricting glutaminolysis in differentiating T <sub>H</sub> 17 cells

2022-02-10

Abstract excerpt

<h4>Objective</h4> 24-Nor-ursodeoxycholic acid (NorUDCA) is a novel therapeutic bile acid for treating primary sclerosing cholangitis (PSC), an immune-mediated cholestatic liver disease. Since PSC strongly associates with inflammatory bowel diseases (IBD) driven by T H 17/Treg imbalance, we aimed to explore NorUDCA’s immunomodulatory potential on intestinal T H 17/Treg balance. <h4>Design</h4> NorUDCA’s impac...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7fe45a23-3125-5bd6-8ba2-9c89bd94c512
DOI
10.1101/2022.02.10.479975
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
24-Nor-ursodeoxycholic acid counteracts T <sub>H</sub> 17/Treg imbalance and ameliorates intestinal inflammation by restricting glutaminolysis in differentiating T <sub>H</sub> 17 cellsDOI 10.1101/2022.02.10.479975
Select a neighboring publication to make it the new centre.